Every patient deserves endocrine clinical assessment, but not every patient needs an indiscriminate hormone panel before obesity treatment begins.
Blog Grid
Parents transmit genes, appetite traits, household environments, early-life exposures, cultural routines, and socioeconomic constraints. Childhood obesity is inherited through a system, not one route.
After semaglutide is stopped, appetite suppression fades, biological pressure to regain can return, and many patients recover a substantial portion of lost weight. The outcome is variable, not inevitable in the same degree.
Tirzepatide generally produces greater average weight loss than semaglutide in obesity trials, but the correct comparison uses obesity brands and doses, not casual brand substitution.
Semaglutide is neither a miracle nor a cosmetic trick. At obesity-treatment doses it can produce clinically important weight loss and health benefits, but maintenance commonly requires continued treatment or another durable strategy.
Two people can eat apparently identical foods and show different weight trajectories because total exposure, absorption, body size, spontaneous activity, appetite compensation, sleep, genetics, microbiome, and measurement error differ.